An overview of the characteristics and methodological standards across systematic reviews with Meta-analysis of efficacy/effectiveness of influenza antiviral drugs

References

• Oliu-Barton M, Pradelski BSR, Algan Y, et al. Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines. Lancet Glob Health. 2021;10:142 –147.
   Web of Science ®Google Scholar
• Smith J, Lipsitch M, Almond JW. New decade of vaccines 3 vaccine production, distribution, access, and uptake. Lancet. 2011;378(9789):428–438.
   PubMed Web of Science ®Google Scholar
• Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50(5):707–714.
   PubMed Web of Science ®Google Scholar
• Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14(2):109–118.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Burk B, Newman F, et al. Resistance of influenza-a virus to amantadine and rimantadine - results of one decade of surveillance. J Infect Dis. 1989;159(3):430–435.
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza a viruses isolated early during the 2005–2006 influenza season in the United States. JAMA-J Am Med Assoc. 2006;295(8):891–894.
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Resp. 2013;7:25–36.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913–923.
   PubMed Web of Science ®Google Scholar
• Hurt AC, Kelly H. Debate regarding oseltamivir use for seasonal and pandemic influenza. Emerg Infect Dis. 2016;22(6):949–955.
   PubMed Web of Science ®Google Scholar
• Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50(7):2395–2402.
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Fry AM. Baloxavir and treatment-emergent resistance: public health insights and next steps. J Infect Dis. 2020;221(3):337–339.
   PubMed Web of Science ®Google Scholar
• Doshi P. Neuraminidase inhibitors-the story behind the Cochrane review. BMJ-Brit Med J. 2009;339(dec07 2):b5164–b5164.
   Google Scholar
• Jones M, Del Mar C. Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf. 2006;5(5):603–608.
   PubMed Web of Science ®Google Scholar
• Vilhelmsson A, Mulinari S. Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics. J Public Health (Oxf). 2018;40(3):646–651.
   PubMed Web of Science ®Google Scholar
• Lugner AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur J Public Health. 2009;19(5):516–520.
   PubMed Web of Science ®Google Scholar
• Haidich AB. Meta-analysis in medical research. Hippokratia. 2010;14(Suppl 1):29–37.
   PubMed Web of Science ®Google Scholar
• Pigott TD, Polanin JR. Methodological guidance papers: high-quality meta-analysis in a systematic review. Rev Educ Res. 2020;90(1):24–46. Feb
   Web of Science ®Google Scholar
• Gopalakrishnan S, Ganeshkumar P. Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J Family Med Prim Care. 2013;2(1):9–14.
   PubMedGoogle Scholar
• Murad MH, Montori VM, Ioannidis JPA, et al. How to read a systematic review and meta-analysis and apply the results to patient care users’ guides to the medical literature. Jama-J Am Med Assoc. 2014;312(2):171–179.
   PubMed Web of Science ®Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions version 6.2 [Internet]. Cochrane. 2021. Available from: www.training.cochrane.org/handbook.
   Google Scholar
• Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
   PubMed Web of Science ®Google Scholar
• Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13(58):1–265.
   PubMed Web of Science ®Google Scholar
• Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess. 2002;6(9):1–87.
   Google Scholar
• Chen JY, Wei SK, Lai CC, et al. A meta-analysis comparing the efficacy and safety of peramivir with other neuraminidase inhibitors for influenza treatment. Medicina (Kaunas). 2020;56(2):63.
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza a and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326(7401):1235.
   PubMed Web of Science ®Google Scholar
• Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract. 2013;30(2):125–133.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemoth. 2010;65(7):1330–1346.
   PubMed Web of Science ®Google Scholar
• Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(apr09 2):g2547–g2547.
   PubMedGoogle Scholar
• Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016 May;20(42):1–242.
   PubMed Web of Science ®Google Scholar
• Higashiguchi M, Matsumoto T, Fujii T. A Meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Antivir Ther. 2018;23(2):157–165.
   PubMed Web of Science ®Google Scholar
• Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512–524.
   PubMed Web of Science ®Google Scholar
• Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011;62(1):14–25.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. The Lancet. 2006;367(9507):303–313.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;10(4):CD008965.
   Google Scholar
• Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(apr09 2):g2545–g2545.
   PubMedGoogle Scholar
• Khazeni N, Bravata DM, Holty JE, et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med. 2009;151(7):464–473.
   PubMed Web of Science ®Google Scholar
• Lee J, Park JH, Jwa H, et al. Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: systematic review and meta-analysis. Yonsei Med J. 2017;58(4):778–785.
   PubMed Web of Science ®Google Scholar
• Malosh RE, Martin ET, Heikkinen T, et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2018;66(10):1492–1500.
   PubMed Web of Science ®Google Scholar
• Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and Meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553–563.
   PubMed Web of Science ®Google Scholar
• Okoli GN, Otete HE, Beck CR, et al. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One. 2014;9(12):e113633.
   PubMed Web of Science ®Google Scholar
• Qiu S, Shen Y, Pan H, et al. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infect Dis (Lond). 2015;47(11):808–819.
   PubMed Web of Science ®Google Scholar
• Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and Meta-analysis of randomised controlled trials. BMJ. 2009;339(aug10 1):b3172–b3172.
   PubMedGoogle Scholar
• Taieb V, Ikeoka H, Ma FF, et al. A network Meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019;35(8):1355–1364.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Jackson R, Cooper K, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009;13(11):iii, ix–xii, 1–246.
   PubMed Web of Science ®Google Scholar
• Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;18(4):CD002744.
   Google Scholar
• McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–46.
   PubMed Web of Science ®Google Scholar
• Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. Syst Rev. 2012;1:7.
   PubMedGoogle Scholar
• The PLoS Medicine Editors. Best practice in systematic reviews: the importance of protocols and registration. PLoS Med. 2011;8(2):e1001009.
   PubMed Web of Science ®Google Scholar
• Garattini S, Liberati A. The risk of bias from omitted research - evidence must be independently sought and free of economic interests. BMJ. 2000;321(7265):845–846.
   PubMedGoogle Scholar
• Crequit P, Trinquart L, Yavchitz A, et al. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer. BMC Med. 2016;14:8.
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz KF, Simera I, et al. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7(2):e1000217.
   PubMed Web of Science ®Google Scholar
• Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990–3007.
   PubMed Web of Science ®Google Scholar
• Michiels B, Van Puyenbroeck K, Verhoeven V, et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.
   PubMed Web of Science ®Google Scholar
• Remschmidt C, Wichmann O, Harder T. Methodological quality of systematic reviews on influenza vaccination. Vaccine. 2014;32(15):1678–1684.
   PubMed Web of Science ®Google Scholar
• De Vito C, Manzoli L, Marzuillo C, et al. A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. Vaccine. 2007;25(52):8794–8806.
   PubMed Web of Science ®Google Scholar
• Zhang C, Huang S, Zheng F, et al. Controversial treatments: an updated understanding of the coronavirus disease 2019. J Med Virol. 2020;92(9):1441–1448.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home. Bmj-Brit Med J. 2021;375:n2602.
   Web of Science ®Google Scholar
• Mucchielli L. Behind the french controversy over the medical treatment of covid-19: the role of the drug industry. J Sociol. 2020;56(4):736–744.
   Web of Science ®Google Scholar